SIGLEC10

SIGLEC10 stands out as a unique member within the siglecs superfamily, possessing a structure resembling adhesion molecules that facilitate sialic acid-dependent cell binding. Functioning as an inhibitory receptor, SIGLEC10 plays a pivotal role in immune responses by regulating them through the induction of tyrosine phosphorylation, recruitment of phosphatases, and negative modulation of B-cell antigen receptor signaling. Furthermore, SIGLEC10 collaborates with CD24 to modulate NK cell responses and autoimmunity, while suppressing cross-presentation by dendritic cells. Additionally, SIGLEC10 is involved in lymphocyte adhesion to endothelial cells, altering the inflammatory microenvironment. Currently, SIGLEC10 has emerged as a crucial target for medical research and drug development, with potential applications including the treatment of non-small cell lung cancer, ovarian cancer, pancreatic cancer, and colorectal cancer.

Popular Product:

Recombinant Human Sialic acid-binding Ig-like lectin 10 (SIGLEC10), partial